BIT Mining
BTCM
Bitdeer Technologies
BTDR
Digihost Technology
DGHI
Mawson Infrastructure
MIGI
Canaan
CAN
US Stock MarketDetailed Quotes
ATXS Astria Therapeutics Inc
- 6.415
- +0.025+0.39%
Trading Feb 26 10:47 ET
362.03MMarket Cap-2.94P/E (TTM)
6.440High6.340Low19.47KVolume6.420Open6.390Pre Close124.58KTurnover0.06%Turnover RatioLossP/E (Static)56.43MShares16.90052wk High1.47P/B199.49MFloat Cap6.31052wk Low--Dividend TTM31.10MShs Float1017.600Historical High--Div YieldTTM1.57%Amplitude2.360Historical Low6.399Avg Price1Lot Size
Astria Therapeutics Inc News
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
Astria Therapeutics Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $26
Express News | Astria Therapeutics Announces Initiation of Phase 1a Trial of Star-0310, a Potential Best-in-Class Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Cuts Target Price to $22
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32
Express News | Astria Therapeutics Inc : Jefferies Raises Target Price to $29 From $27
Astria Therapeutics Announces ALPHA-ORBIT Phase 3 Trial Design For Navenibart In HAE; Features 3- And 6-Month Dosing, Primary Analysis At 6 Months; Expected Q1 2025 Initiation And Early 2027 Results; Strong Financial Position Supports Until Top-Line...
Express News | Astria Therapeutics Inc: Alpha-Orbit Top-Line Results Anticipated in Early 2027.
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Top Premarket Decliners
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $23
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $32
Express News | Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.